Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308986514> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W4308986514 abstract "In this study, we investigated the ability of prostate-specific antigen (PSA) 12 months after (nPSA12) external beam radiotherapy (EBRT) combined with androgen deprivation therapy (ADT) to predict biochemical recurrence-free survival (BRFS), overall survival (OS), and prostate cancer-specific mortality (PCSM) in intermediate- and high-risk prostate cancer patients.We retrospectively reviewed the clinical data of 338 intermediate- and high-risk prostate cancer patients treated with EBRT with ADT at our institution between 2000 and 2018. The median radiation dose was 76 Gy, the median initial PSA level was 17 ng/mL (range, 1-228 ng/mL), and the median duration of ADT was 24 months (range, 6-167 months). The median PSA level 1 months after EBRT was 0.06 ng/mL (range, 0-25.6 ng/mL). Univariate and multivariate analyses were performed. Patient survival was assessed using the Kaplan-Meier method and Cox proportional hazards regression analyses.The median follow-up time was 5 years (range, 1-20 years). Multivariate analysis revealed that nPSA was an independent and significant factor associated with OS, PCSM, and BRFS (P = 0.008, P = 0.001, P = 0.04). Furthermore, the time to nPSA12 was an independent predictor of PCSM and BRFS (P = 0.042, P = 0.021). Pelvic irradiation was also significantly associated with worse OS and PCSM (P = 0.004, P = 0.01). Additionally, age (≤ 70 or > 70 years) and hormone therapy duration (6 months, 1-3 years, or > 3 years) were significantly associated with OS and PCSM, respectively (P = 0.004, P = 0.02). For high risk, nPSA and nPSA12 were an independent predictor for BRFS. (P = 0.021, P = 0.029) CONCLUSION: The nPSA12 level of > 0.06 ng/mL may independently predict worse PCSM and BRFS in intermediate- and high-risk prostate cancer patients undergoing EBRT and ADT. Additionally, for high risk, nPSA > 0.06 ng/mL and nPSA12 > 0.06 ng/mL may independently predict worse BRFS." @default.
- W4308986514 created "2022-11-20" @default.
- W4308986514 creator A5025412537 @default.
- W4308986514 creator A5067163626 @default.
- W4308986514 creator A5079913944 @default.
- W4308986514 date "2022-11-15" @default.
- W4308986514 modified "2023-09-26" @default.
- W4308986514 title "Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients" @default.
- W4308986514 cites W1969753482 @default.
- W4308986514 cites W1977382117 @default.
- W4308986514 cites W1979665150 @default.
- W4308986514 cites W1979819510 @default.
- W4308986514 cites W1996422254 @default.
- W4308986514 cites W1996550652 @default.
- W4308986514 cites W2040818579 @default.
- W4308986514 cites W2045858226 @default.
- W4308986514 cites W2062412101 @default.
- W4308986514 cites W2074421032 @default.
- W4308986514 cites W2081411497 @default.
- W4308986514 cites W2098307421 @default.
- W4308986514 cites W2105386786 @default.
- W4308986514 cites W2106285196 @default.
- W4308986514 cites W2110881680 @default.
- W4308986514 cites W2112064853 @default.
- W4308986514 cites W2133937721 @default.
- W4308986514 cites W2134766389 @default.
- W4308986514 cites W2142359566 @default.
- W4308986514 cites W2161749968 @default.
- W4308986514 cites W2171210159 @default.
- W4308986514 cites W2178139012 @default.
- W4308986514 cites W2753540085 @default.
- W4308986514 cites W2954375476 @default.
- W4308986514 cites W4229831433 @default.
- W4308986514 doi "https://doi.org/10.1186/s12894-022-01125-1" @default.
- W4308986514 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36376849" @default.
- W4308986514 hasPublicationYear "2022" @default.
- W4308986514 type Work @default.
- W4308986514 citedByCount "0" @default.
- W4308986514 crossrefType "journal-article" @default.
- W4308986514 hasAuthorship W4308986514A5025412537 @default.
- W4308986514 hasAuthorship W4308986514A5067163626 @default.
- W4308986514 hasAuthorship W4308986514A5079913944 @default.
- W4308986514 hasBestOaLocation W43089865141 @default.
- W4308986514 hasConcept C121608353 @default.
- W4308986514 hasConcept C126322002 @default.
- W4308986514 hasConcept C126894567 @default.
- W4308986514 hasConcept C143998085 @default.
- W4308986514 hasConcept C144301174 @default.
- W4308986514 hasConcept C207103383 @default.
- W4308986514 hasConcept C2775908122 @default.
- W4308986514 hasConcept C2776235491 @default.
- W4308986514 hasConcept C2777899217 @default.
- W4308986514 hasConcept C2780192828 @default.
- W4308986514 hasConcept C2780275930 @default.
- W4308986514 hasConcept C2781406297 @default.
- W4308986514 hasConcept C38180746 @default.
- W4308986514 hasConcept C44249647 @default.
- W4308986514 hasConcept C50382708 @default.
- W4308986514 hasConcept C509974204 @default.
- W4308986514 hasConcept C530470458 @default.
- W4308986514 hasConcept C71924100 @default.
- W4308986514 hasConceptScore W4308986514C121608353 @default.
- W4308986514 hasConceptScore W4308986514C126322002 @default.
- W4308986514 hasConceptScore W4308986514C126894567 @default.
- W4308986514 hasConceptScore W4308986514C143998085 @default.
- W4308986514 hasConceptScore W4308986514C144301174 @default.
- W4308986514 hasConceptScore W4308986514C207103383 @default.
- W4308986514 hasConceptScore W4308986514C2775908122 @default.
- W4308986514 hasConceptScore W4308986514C2776235491 @default.
- W4308986514 hasConceptScore W4308986514C2777899217 @default.
- W4308986514 hasConceptScore W4308986514C2780192828 @default.
- W4308986514 hasConceptScore W4308986514C2780275930 @default.
- W4308986514 hasConceptScore W4308986514C2781406297 @default.
- W4308986514 hasConceptScore W4308986514C38180746 @default.
- W4308986514 hasConceptScore W4308986514C44249647 @default.
- W4308986514 hasConceptScore W4308986514C50382708 @default.
- W4308986514 hasConceptScore W4308986514C509974204 @default.
- W4308986514 hasConceptScore W4308986514C530470458 @default.
- W4308986514 hasConceptScore W4308986514C71924100 @default.
- W4308986514 hasIssue "1" @default.
- W4308986514 hasLocation W43089865141 @default.
- W4308986514 hasLocation W43089865142 @default.
- W4308986514 hasLocation W43089865143 @default.
- W4308986514 hasLocation W43089865144 @default.
- W4308986514 hasOpenAccess W4308986514 @default.
- W4308986514 hasPrimaryLocation W43089865141 @default.
- W4308986514 hasRelatedWork W1980188241 @default.
- W4308986514 hasRelatedWork W2030798726 @default.
- W4308986514 hasRelatedWork W2038565121 @default.
- W4308986514 hasRelatedWork W2127440557 @default.
- W4308986514 hasRelatedWork W2148869351 @default.
- W4308986514 hasRelatedWork W2373651588 @default.
- W4308986514 hasRelatedWork W2897445903 @default.
- W4308986514 hasRelatedWork W3129209394 @default.
- W4308986514 hasRelatedWork W4281788288 @default.
- W4308986514 hasRelatedWork W95247034 @default.
- W4308986514 hasVolume "22" @default.
- W4308986514 isParatext "false" @default.
- W4308986514 isRetracted "false" @default.
- W4308986514 workType "article" @default.